Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB) reported strong financial results for Q3 2021, with revenue reaching $34.9 million, an 83% year-over-year increase. The company installed 44 Sequel II/IIe systems during the quarter, bringing the total installed base to 326 systems. Gross profit soared to $15.4 million, reflecting a 117% increase and a gross margin of 44%. Despite this growth, operating expenses surged to $89.8 million, influenced by substantial stock-based compensation. Net income stood at $16.5 million, a significant turnaround from the $23.7 million loss in Q3 2020.
PacBio Expands Genetic Testing Services
On November 2, 2021, PacBio announced a partnership with Prenetics Group Limited to enhance genetic screening services, including carrier and cancer-risk screenings across Hong Kong, Southeast Asia, and the UK. Utilizing PacBio’s SMRT HiFi sequencing technology, Prenetics aims to improve accuracy in detecting genetic mutations through its Circle Medical offering. This collaboration is regarded as a significant step in clinical genomics, with potential implications for personalized healthcare.
Pacific Biosciences (NASDAQ: PACB) will conduct its third quarter 2021 financial results conference call on November 2, 2021, at 4:30 PM ET. The call will be available via webcast on the company’s investor relations website. Interested parties can access the call by using the toll-free number 888.366.7247 or the international number 707.287.9330, with Conference ID 5129207. Pacific Biosciences focuses on long-read sequencing technology, empowering researchers in diverse fields such as human biomedical research and microbiology.
Pacific Biosciences (NASDAQ: PACB) announced a partnership with the European Reference Genome Atlas (ERGA) to enhance biodiversity research through high-quality genomic data. The collaboration aims to generate complete, error-free genome assemblies for 200,000 European plant and animal species by 2030, supporting conservation efforts. PacBio's HiFi Sequencing technology ensures reliable genetic mapping. This initiative aligns with PacBio's ongoing commitment to biodiversity genomics and global collaborative projects.
Pacific Biosciences (NASDAQ: PACB) announced on September 24, 2021, that its Compensation Committee granted stock options for 100,000 shares and restricted stock units (RSUs) for 50,000 shares to a new employee. These awards are part of the 2020 Inducement Equity Incentive Plan, introduced to attract new talent. The stock options have an exercise price of $27.99, equal to the stock's closing price on the grant date. The vesting schedule includes milestones at one year and monthly thereafter for options, while RSUs vest over four years.
Pacific Biosciences (PACB) has completed its acquisition of Omniome, enhancing its position in the sequencing market by combining long-read and short-read technologies. This acquisition is expected to accelerate the adoption of PacBio’s SMRT Sequencing platform, allowing for increased accuracy and sensitivity in clinical applications. The transaction, valued at approximately $316 million in cash and stock, is supported by a $300 million private placement financing. The integration aims to unlock new markets and improve cancer diagnostics.
Pacific Biosciences (NASDAQ: PACB) announced that its executives will participate in several upcoming investor conferences. The events include the Wells Fargo Virtual Healthcare Conference on September 10, Morgan Stanley's 19th Annual Global Healthcare Conference on September 14, and the 2021 Cantor Virtual Global Healthcare Conference on September 28. Each fireside chat will provide insights into the company's advancements in long-read sequencing technology. Live webcasts will be available on the company’s investor page, with replays accessible for 30 days post-event.
Pacific Biosciences of California (NASDAQ: PACB) announced that its executives will speak at the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021, at 4:00 pm Eastern Time (1:00 pm Pacific Time). The event will feature a panel discussion, and live webcasts will be accessible on the company's investor page, with replays available for at least 30 days. Pacific Biosciences specializes in highly accurate long-read sequencing technology, empowering life scientists globally to explore genetic variations for numerous applications.
Pacific Biosciences (PACB) reported record revenue of $30.6 million for Q2 2021, an increase of 79% from Q2 2020. The company placed 38 Sequels II/IIe systems, increasing the installed base to 282 units. Instrument revenue rose to $14.3 million, with consumables at $12.2 million. Gross profit surged to $13.8 million, yielding a gross margin of 45%. However, operating expenses rose to $51.3 million, leading to a net loss of $41.0 million. The company also announced plans to acquire Omniome and raised $300 million in a private placement.
Pacific Biosciences (PACB) has announced the acquisition of Circulomics Inc., a firm specializing in high-quality DNA extraction products essential for genomic workflows. This acquisition aims to enhance the front end of PacBio's sequencing workflows through Circulomics' proven Nanobind technology, which aids in obtaining high molecular weight (HMW) DNA from various samples. The financial terms of the deal were undisclosed, and its pro forma impact is not expected to be material in 2021. The company will provide further details during its fiscal second-quarter earnings call.